全文获取类型
收费全文 | 9257篇 |
免费 | 642篇 |
国内免费 | 84篇 |
专业分类
耳鼻咽喉 | 72篇 |
儿科学 | 224篇 |
妇产科学 | 67篇 |
基础医学 | 1071篇 |
口腔科学 | 214篇 |
临床医学 | 657篇 |
内科学 | 2678篇 |
皮肤病学 | 403篇 |
神经病学 | 461篇 |
特种医学 | 424篇 |
外科学 | 1572篇 |
综合类 | 32篇 |
一般理论 | 1篇 |
预防医学 | 250篇 |
眼科学 | 135篇 |
药学 | 505篇 |
中国医学 | 11篇 |
肿瘤学 | 1206篇 |
出版年
2024年 | 10篇 |
2023年 | 146篇 |
2022年 | 296篇 |
2021年 | 468篇 |
2020年 | 230篇 |
2019年 | 304篇 |
2018年 | 397篇 |
2017年 | 337篇 |
2016年 | 369篇 |
2015年 | 353篇 |
2014年 | 450篇 |
2013年 | 456篇 |
2012年 | 801篇 |
2011年 | 802篇 |
2010年 | 409篇 |
2009年 | 330篇 |
2008年 | 560篇 |
2007年 | 618篇 |
2006年 | 535篇 |
2005年 | 499篇 |
2004年 | 423篇 |
2003年 | 325篇 |
2002年 | 283篇 |
2001年 | 73篇 |
2000年 | 58篇 |
1999年 | 73篇 |
1998年 | 48篇 |
1997年 | 35篇 |
1996年 | 27篇 |
1995年 | 23篇 |
1994年 | 20篇 |
1993年 | 14篇 |
1992年 | 28篇 |
1991年 | 25篇 |
1990年 | 23篇 |
1989年 | 21篇 |
1988年 | 11篇 |
1987年 | 11篇 |
1986年 | 14篇 |
1985年 | 11篇 |
1984年 | 8篇 |
1983年 | 6篇 |
1979年 | 8篇 |
1977年 | 3篇 |
1975年 | 3篇 |
1974年 | 4篇 |
1973年 | 8篇 |
1972年 | 3篇 |
1968年 | 3篇 |
1966年 | 3篇 |
排序方式: 共有9983条查询结果,搜索用时 15 毫秒
71.
Suzuki N Kameyama K Hirao T Susumu N Mukai M Aoki D 《The journal of obstetrics and gynaecology research》2007,33(2):203-206
Small cell carcinoma is a rare form of ovarian cancer with a poor prognosis. It is divided into two types, the hypercalcemic and the pulmonary type, of which the latter is extremely rare. A 49-year-old woman presented with an acute abdomen and was suspected to have torsion of a left ovarian tumor, which was followed up with an emergency operation. Postoperative pathological examination gave a diagnosis of the pulmonary type of ovarian small cell carcinoma. Six courses of paclitaxel and carboplatin therapy were given as adjuvant chemotherapy. The patient has survived for 36 months without recurrence. Here we present an extremely rare patient with the pulmonary type of ovarian small cell carcinoma. 相似文献
72.
Tomoki Kuge Kiyoharu Fukushima Yuki Matsumoto Haruko Saito Yuko Abe Eri Akiba Kako Haduki Tadayoshi Nitta Akira Kawano Michio Tanaka Yumi Hattori Takahiro Kawasaki Takanori Matsuki Takayuki Shiroyama Daisuke Motooka Kazuyuki Tsujino Keisuke Miki Masahide Mori Seigo Kitada Shota Nakamura Tetsuya Iida Atsushi Kumanogoh Hiroshi Kida 《Emerging infectious diseases》2022,28(7):1437
Unidentified Mycobacterium species are sometimes detected in respiratory specimens. We identified a novel Tsukamurella species (Tsukamurella sp. TY48, RIMD 2001001, CIP 111916T), Tsukamurella toyonakaense, from a patient given a misdiagnosis of nontuberculous mycobacterial pulmonary disease caused by unidentified mycobacteria. Genomic identification of this Tsukamurella species helped clarify its clinical characteristics and epidemiology. 相似文献
73.
Daisuke Takada Susumu Kunisawa Akira Kikuno Tomoko Iritani Yuichi Imanaka 《Journal of epidemiology / Japan Epidemiological Association》2022,32(7):323
BackgroundThe transtheoretical model (TTM) is composed of the multiple stages according to patient’s consciousness and is believed to lead people to realize the importance of healthier behaviors. We examined the association of TTM stages with the decline of estimated glomerular filtration rate (eGFR).MethodsWe used the annual health checkup data and health insurance claims data of the Japan Health Insurance Association in Kyoto Prefecture between April 2012 and March 2016. TTM stages of change obtained from questionnaires at the first health checkup and categorized into six groups. The primary outcome was defined as a more than 30% decline in eGFR from the first health checkup. We fitted multivariable Cox proportional-hazards model for time-to-event analyses adjusting for age, sex, eGFR, body mass index, blood pressure, blood sugar, dyslipidemia, uric acid, urinary protein, and existence of kidney diseases at first health checkup.ResultsWe analyzed 239,755 employees and the mean follow-up was 2.9 (standard deviation, 1.2) years. As compared with the stage 1 group, the risk of eGFR decline was significantly low in the stage 3 group (hazard ratio [HR] 0.77; 95% confidence interval [CI], 0.65–0.91); stage 4 group (HR 0.80; 95% CI, 0.65–0.98); and stage 5 group (HR 0.79; 95% CI, 0.66–0.95).ConclusionCompared with the precontemplation stage (stage 1), the preparation, action and maintenance stages (stages 3, 4, and 5), were associated with a lower risk of eGFR decline.Key words: transtheoretical model, chronic kidney disease, kidney injury, stage of change, more than 30% decline in estimated glomerular filtration rate 相似文献
74.
Tomoko Akahane Kenta Masuda Akira Hirasawa Yusuke Kobayashi Arisa Ueki Miho Kawaida Kumiko Misu Kohei Nakamura Shimpei Nagai Tatsuyuki Chiyoda Wataru Yamagami Shigenori Hayashi Fumio Kataoka Kouji Banno Kokichi Sugano Hajime Okita Kenjiro Kosaki Hiroshi Nishihara Daisuke Aoki 《Journal Of Gynecologic Oncology》2022,33(4)
ObjectivePrecursor lesions may be identified in fallopian tube tissue after risk-reducing salpingo-oophorectomy (RRSO) in patients with pathogenic variants of BRCA1/2. Serous tubal intraepithelial carcinoma (STIC) is considered a precursor of high-grade serous carcinoma, whereas the significance of the p53 signature remains unclear. In this study, we investigated the relationship between the p53 signature and the risk of ovarian cancer.MethodsWe analyzed the clinicopathological findings and conducted DNA sequencing for TP53 variants of p53 signatures and STIC lesions isolated using laser capture microdissection in 13 patients with pathogenic variants of BRCA1/2 who underwent RRSO and 17 control patients with the benign gynecologic disease.Results TP53 pathogenic variants were detected significantly higher in RRSO group than control (p<0.001). No difference in the frequency of p53 signatures were observed between groups (53.8% vs 29.4%; p=0.17). TP53 sequencing and next-generation sequencing analysis in a patient with STIC and occult cancer revealed 2 TP53 mutations causing different p53 staining for STICs and another TP53 mutation shared between STIC and occult cancer.ConclusionThe sequence analysis for TP53 revealed 2 types of p53 signatures, one with a risk of progression to STIC and ovarian cancer with pathological variants in TP53 and the other with a low risk of progression without pathological variants in TP53 as seen in control. 相似文献
75.
Daisuke Yabe Yuichiro Yamada Kohei Kaku Tomoyuki Nishida Toshihiro Sato Yutaka Seino 《Journal of diabetes investigation.》2022,13(7):1161
Aims/IntroductionMany East Asians with type 2 diabetes are elderly and have a low body mass index (BMI), especially in ''super‐aged'' populations, such as Japan. This post‐hoc analysis assessed once‐weekly semaglutide efficacy and safety in Japanese individuals with type 2 diabetes across baseline age and BMI subgroups.Materials and MethodsData were derived from the Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes (SUSTAIN) Japan monotherapy and SUSTAIN Japan oral antidiabetes drug (OAD) combination trials comparing once‐weekly semaglutide with sitagliptin or OADs, respectively. Participants were grouped by baseline age (<65 and ≥65 years) and/or BMI (<25 and ≥25 kg/m2). Reductions from baseline in glycosylated hemoglobin and bodyweight (efficacy), and adverse events (safety) were assessed.ResultsIn this analysis, participants from the SUSTAIN Japan monotherapy trial (n = 308; n per subgroup; range, 8–73) and SUSTAIN Japan OAD combination trial (n = 601; n per subgroup; range, 20–168) were included. Reductions in glycosylated hemoglobin and bodyweight were numerically greater with semaglutide versus comparators across all age and BMI subgroups. Reductions from baseline in glycosylated hemoglobin ranged from –1.7 to –2.1 with semaglutide 0.5 mg, –1.8 to –2.4 with semaglutide 1.0 mg and –0.6 to –1.0 with comparators. Corresponding ranges for bodyweight (kg) were –1.0 to –2.5, –2.4 to –4.3 and 1.0 to –1.0 kg, respectively. The safety profile of semaglutide was broadly similar across BMI and age subgroups.ConclusionsIn this post‐hoc analysis with modest subgroup numbers, once‐weekly semaglutide appeared consistently more efficacious versus comparators across age and BMI subgroups in Japanese patients, with a similar safety profile. 相似文献
76.
Hiroyuki Hisada Yoshiki Sakaguchi Kaori Oshio Satoru Mizutani Hideki Nakagawa Junichi Sato Dai Kubota Miho Obata Rina Cho Sayaka Nagao Yuko Miura Hiroya Mizutani Daisuke Ohki Seiichi Yakabi Yu Takahashi Naomi Kakushima Yosuke Tsuji Nobutake Yamamichi Mitsuhiro Fujishiro 《Current oncology (Toronto, Ont.)》2022,29(7):4678
Although the mortality rates of gastric cancer (GC) are gradually declining, gastric cancer is still the fourth leading cause of cancer-related death worldwide. This may be due to the high rate of patients who are diagnosed with GC at advanced stages. However, in countries such as Japan with endoscopic screening systems, more than half of GCs are discovered at an early stage, enabling endoscopic resection (ER). Especially after the introduction of endoscopic submucosal dissection (ESD) in Japan around 2000, a high en bloc resection rate allowing pathological assessment of margin and depth has become possible. While ER is a diagnostic method of treatment and may not always be curative, it is widely accepted as standard treatment because it is less invasive than surgery and can provide an accurate diagnosis for deciding whether additional surgery is necessary. The curability of ER is currently assessed by the completeness of primary tumor removal and the possibility of lymph node metastasis. This review introduces methods, indications, and curability criteria for ER of EGC. Despite recent advances, several problems remain unsolved. This review will also outline the latest evidence concerning future issues. 相似文献
77.
Tetsuaki Ban Shin-ichiro Fujiwara Rui Murahashi Hirotomo Nakajima Takashi Ikeda Sae Matsuoka Yumiko Toda Shin-ichiro Kawaguchi Shoko Ito Takashi Nagayama Kento Umino Daisuke Minakata Hirofumi Nakano Kaoru Morita Masahiro Ashizawa Chihiro Yamamoto Kaoru Hatano Kazuya Sato Ken Ohmine Yoshinobu Kanda 《Internal medicine (Tokyo, Japan)》2022,61(7):989
Objective Peripherally inserted central catheters (PICCs) are widely used in patients with hematologic malignancies. However, the risks of PICC-related complications during chemotherapy for acute myeloid leukemia (AML) are not fully understood. Methods We conducted a retrospective review of 128 adult patients with AML who received induction therapy by way of PICC insertion between 2012 and 2019. Results The median duration of PICC insertion was 30 days. The incidence rate of catheter-related bloodstream infection (CRBSI) was 2.4% at 30 days, and women were more likely to suffer from CRBSI than men. Local reactions at the insertion site were observed in 56 patients; however, these events did not predict CRBSI. The incidence rates of catheter-related thrombosis (CRT) were 1.6% at 30 days. Obesity put patients at an increased risk for CRT. Unexpected PICC removal occurred in 59 patients, and women were at a higher risk of catheter removal than men. Conclusion Low PICC-related complication rates, possibly associated with high rates of catheter removal, were observed during intensive chemotherapy for AML. Women and obese patients require careful monitoring of their PICC. Procedures to achieve appropriate PICC removal without increasing the complication rate need to be considered. 相似文献
78.
79.
Yoshida H Mamada Y Taniai N Mizuguchi Y Kakinuma D Ishikawa Y Kanda T Matsumoto S Bando K Akimaru K Tajiri T 《Journal of Hepato-Biliary-Pancreatic Surgery》2008,15(2):178-182
Background/Purpose According to the General rules for the clinical and pathological study of primary liver cancer, compiled by the Liver Cancer Study Group of Japan, ruptured hepatocellular carcinoma (HCC) is classified as stage 4, even
if the tumor is small and solitary. We examined the long-term results of elective hepatectomy for the treatment of ruptured
HCC.
Methods A first hepatectomy was performed without operative death in 193 patients with HCC. Ten patients had ruptured HCC (ruptured
group) and 183 patients had nonruptured HCC (nonruptured group). The extension of HCC was macroscopically classified as stage
1 in 23 patients, stage 2 in 71, stage 3 in 53, and stage 4 in 46.
Results Cumulative survival rates in the ruptured group at 1, 5, and 10 years were 90.0%, 67.5%, and 20.3%, respectively. The cumulative
survival rate was lower in patients with stage 4 disease in the nonruptured group than that in patients in the ruptured group
(P < 0.05). Cumulative survival rates did not differ significantly between patients in the ruptured group and those with stage
2 or stage 3 disease.
Conclusions Survival rates after elective hepatectomy in patients with ruptured HCC are good, even if the disease is classified as stage
4. 相似文献
80.
Effect of the XIAP inhibitor Embelin on TRAIL-induced apoptosis of pancreatic cancer cells 总被引:1,自引:0,他引:1
Mori T Doi R Kida A Nagai K Kami K Ito D Toyoda E Kawaguchi Y Uemoto S 《The Journal of surgical research》2007,142(2):281-286
BACKGROUND: Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a potent inducer of apoptosis in a wide variety of tumor cells, while it has no toxicity for the majority of normal cells.Therefore, TRAIL may be a suitable agent for anticancer therapy. We previously reported that a number of pancreatic cancer cell lines show resistance to TRAIL-induced apoptosis via overexpression of XIAP and FLIP. The present study was conducted to further examine TRAIL-based therapeutic strategies by aiming to restore functional apoptotic pathways in resistant pancreatic cancer cells. METHODS: In various pancreatic cancer cell lines, TRAIL-induced apoptosis was evaluated in the presence or absence of an XIAP-inhibitor (Smac peptide). Second, TRAIL-induced apoptosis was evaluated in TRAIL-resistant AsPC-1 cells with or without FLIP antisense. Third, the combined effect of Smac peptide and FLIP antisense was tested, and the activation of apoptosis-related caspases and poly (ADP-ribose) polymerase was evaluated. Finally, TRAIL-induced apoptosis was evaluated in the presence or absence of FLIP antisense and an XIAP inhibitor (embelin). RESULTS: Smac peptide enhanced TRAIL-induced apoptosis in a dose-dependent manner for several pancreatic cancer cell lines, but showed no effect on TRAIL-resistant AsPC-1 cells. Smac peptide alone had no influence on cell viability. TRAIL-induced apoptosis was restored in TRAIL-resistant AsPC-1 cells by exposure to FLIP antisense, which suppressed the expression of FLIP. The effect of TRAIL was augmented by the combination of FLIP antisense and Smac peptide. Similarly, TRAIL-induced apoptosis was restored by the combination of FLIP antisense and embelin. Activation of apoptotic caspases and cleavage of poly (ADP-ribose) polymerase was observed after sensitization of TRAIL-resistant pancreatic cancer cells. CONCLUSIONS: Pancreatic cancer cells gain resistance to TRAIL-induced apoptosis via expression of the antiapoptotic proteins XIAP and FLIP. Smac peptide and FLIP antisense could restore the apoptotic effect of TRAIL. An XIAP inhibitor, embelin, enhanced the effect of TRAIL in the presence of FLIP antisense. These findings may provide useful information for the development of TRAIL-based therapeutic strategies by restoring functional apoptotic pathways in resistant pancreatic cancer cells. In addition, a low molecular weight XIAP inhibitor like embelin could be a lead compound for the development of effective XIAP inhibitors. 相似文献